Eli Lilly opposes push to codify Trump drug-price deals into law

Eli Lilly CEO David Ricks said the company opposes efforts to enshrine the White House’s "most favored nation" (MFN)‑style drug‑pricing agreements into statute, framing the move as a policy that could harm innovation and patient access. Ricks’ comments represent a clear executive pushback as the administration seeks broader, legislative backing for its pricing agenda.

The dispute follows voluntary agreements announced last year between the administration and major drugmakers, including Eli Lilly and Novo Nordisk, to lower certain GLP‑1 drug prices for Medicare, Medicaid and some cash payers. The White House has promoted the TrumpRx platform and asked Congress to codify aspects of those deals, but industry leaders warn that converting voluntary arrangements into law would be a different, more disruptive step.

From a market perspective, Lilly’s strong GLP‑1 sales have so far supported revenue growth, but the policy debate has increased political risk for valuation. Analysts note that while short‑term volatility is possible if legislation advances, the company’s product momentum and sales trajectory remain key drivers for medium‑term earnings. Investors are monitoring price reactions and guidance revisions closely.

Broader industry reaction underscores a divide: policymakers argue for aggressive measures to reduce U.S. drug costs, while many manufacturers caution that hard‑wiring international reference prices into U.S. law could import the downsides of other markets without addressing structural issues in the U.S. health‑care system. That tension—between price relief goals and innovation incentives—frames the next phase of negotiations.

Looking ahead, the path forward will depend on how Congress responds to the administration’s request, whether more firms negotiate voluntary terms, and how regulators design any pilot or Medicare models. Market participants expect a period of close policy monitoring and scenario analysis; should legislation progress, analysts will update revenue and margin assumptions to reflect any legally binding pricing framework.